The trajectory of the erectile dysfunction drug presents a complex picture for shareholders. While the initial release generated significant returns, the end of its patent opened the floodgates to cheaper alternatives, https://tamzinylrn250300.diowebhost.com/97019727/sildenafil-and-big-pharma-a-volatile-bet